Clinical Trial

Breast Cancer Response Evaluation for Individualized Therapy

Study Description

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY

The current study (BREVITY) aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies at ~2-3 weeks after the initiation of neoadjuvant chemotherapy.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Procedure - Core needle biopsy

1st core needle biopsy for RDA 2 specimens: Time Point: ~2-3 weeks after initiation of 1st cycle of chemotherapy; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin. 2nd core needle biopsy for RDA: Time Point: if therapy is changed (as part of SoC), a second biopsy ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 da ...read more on ClinicalTrials.org

Additional Information

Official Study Title

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)

Clinical Trial ID

NCT03524430

ParticipAid ID

wdLNDa